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BACKGROUND: Low birthweight has been associated with a higher 
risk of hypertension, type 2 diabetes mellitus (T2D), and cardiovascular 
disease. The Barker hypothesis posits that intrauterine growth restriction 
resulting in lower birthweight is causal for these diseases, but causality is 
difficult to infer from observational studies.
METHODS: We performed regression analyses to assess associations of 
birthweight with cardiovascular disease and T2D in 237 631 individuals 
from the UK Biobank. Further, we assessed the causal relationship of such 
associations using Mendelian randomization. 
RESULTS: In the observational analyses, birthweight showed inverse 
associations with systolic and diastolic blood pressure (β, −0.83 and 
−0.26; per raw unit in outcomes and SD change in birthweight; 95% 
confidence interval [CI], −0.90 to −0.75 and −0.31 to −0.22, respectively), 
T2D (odds ratio, 0.83; 95% CI, 0.79–0.87), lipid-lowering treatment (odds 
ratio, 0.84; 95% CI, 0.81–0.86), and coronary artery disease (hazard 
ratio, 0.85; 95% CI, 0.78–0.94), whereas the associations with adult body 
mass index and body fat (β, 0.04 and 0.02; per SD change in outcomes 
and birthweight; 95% CI, 0.03–0.04 and 0.01–0.02, respectively) were 
positive. The Mendelian randomization analyses indicated inverse causal 
associations of birthweight with low-density lipoprotein cholesterol, 
2-hour glucose, coronary artery disease, and T2D and positive causal 
association with body mass index but no associations with blood pressure.
CONCLUSIONS: Our study indicates that lower birthweight, used as 
a proxy for intrauterine growth retardation, is causally related with 
increased susceptibility to coronary artery disease and T2D. This causal 
relationship is not mediated by adult obesity or hypertension.
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The association between low birthweight and in-creased risk of coronary artery disease (CAD) in adult life was first demonstrated by the British 
epidemiologist David Barker in a landmark paper in the 
Lancet in 1989.1 This observation was later extended us-
ing a longitudinal cohort study of 8760 participants with 
growth trajectories during childhood.2 In this study, indi-
viduals with a low birthweight increased their weight rap-
idly after 2 years of age and had increased risk of insulin 
resistance and CAD in adult life. In 1992, Barker proposed 
that these relationships could be explained by what he 
called the thrifty phenotype hypothesis3 attributing the 
association between poor fetal and infant growth and 
subsequent increased cardiovascular risk to arise from a 
compensatory response to nutritional deprivation in early 
life, resulting in permanent changes in glucose-insulin 
metabolism and somatic growth lasting into adulthood. 
Decreased insulin secretion and increased insulin resis-
tance in combination with effects of obesity, aging, and 
physical inactivity are the most important factors leading 
to type 2 diabetes mellitus (T2D),3 but they are also inde-
pendent risk factors for CAD, stroke, and hypertension.4
Still, it is not yet clear whether birthweight plays a 
causal role in the development of these outcomes as pos-
ited in the Barker hypothesis or whether other phenom-
ena, such as confounding factors (maternal smoking, 
socioeconomics level, ethnicity), have resulted in spurious 
associations in previous observational studies. We want-
ed to investigate causal mechanisms using the Mende-
lian randomization (MR) approach. This method has the 
ability to infer a causal relationship between a risk fac-
tor and a disease, using genetic markers as a proxy for a 
modifiable exposure. In the case of birthweight, it can be 
considered as a summary measure reflecting several intra-
uterine exposures that collectively influence fetal growth. 
In this MR study, we used birthweight-associated variants 
as a proxy for intrauterine growth to examine whether 
reduced intrauterine growth contributes causally to later 
life complex diseases. Two smaller prior MR studies indi-
cated a causal association between low birthweight and 
T2D5 but not with lipids or CAD.6 However, these studies 
were hampered by weak instrumental variables includ-
ing only 5 and 7 single-nucleotide polymorphisms (SNPs), 
respectively, resulting in limited statistical power. Further-
more, these studies did not address the relationship of 
birthweight with other important cardiovascular diseases 
and risk factors, including atrial fibrillation (AF), ischemic 
stroke (IS), blood pressure, body mass index (BMI), waist-
to-hip ratio (WHR), high-density lipoproteins (HDL), low-
density lipoprotein (LDL), triglycerides, 2-hour glucose, 
fasting glucose, and fasting insulin.
The aims of the present study were to (1) describe 
the relationships of self-reported birthweight to several 
cardiovascular traits in 237 631 participants of the UK 
Biobank (UKB) and (2) delineate any causal relationships 
between birthweight and CAD, AF, IS, and T2D, and 
risk factors for these diseases (systolic blood pressure 
[SBP] and diastolic blood pressure [DBP], BMI, WHR, 
HDL, LDL, triglycerides, 2-hour glucose, fasting glucose, 
and fasting insulin) by 2-sample MR analysis using sum-
mary statistics from the largest available genome-wide 
association study (GWAS) meta-analyses.
METHODS
The authors declare that all data are publicly available in the 
UKB repository.7 The UKB study was approved by the North 
West Multi-Centre Research Ethics Committee, and all par-
ticipants provided written informed consent. Data on birth-
weight; CAD; AF; IS; SBP and DBP; BMI and WHR; HDL, LDL, 
and triglycerides; T2D; 2-hour glucose, fasting glucose, and 
fasting insulin have been contributed by EGG (Early Growth 
Genetics),8 CARDIoGRAMplusC4D (Coronary ARtery DIsease 
Genome wide Replication and Meta-analysis [CARDIoGRAM] 
CLINICAL PERSPECTIVE
Low birthweight has been associated with a 
higher risk of hypertension, type 2 diabetes mel-
litus, and cardiovascular disease in epidemio-
logical studies. The Barker hypothesis posits that 
intrauterine growth restriction resulting in lower 
birthweight is causal for these diseases, but cau-
sality and mechanisms are difficult to infer from 
observational studies. We address this important 
question with Mendelian randomization analysis 
to shed light on biological mechanisms behind 
these complex traits. In traditional observational 
analyses, self-reported birth weight was inversely 
associated with blood pressure, coronary artery 
disease, and type 2 diabetes mellitus and directly 
associated with body mass index and body fat 
percentage. Using Mendelian randomization, we 
established that lower birthweight was causally 
related to higher low-density lipoprotein choles-
terol and 2-hour glucose and higher risk of coro-
nary artery disease and type 2 diabetes mellitus. 
Further, our study suggests that increased birth 
weight is causally associated with increased body 
mass index but not causally associated with blood 
pressure. This is the largest Mendelian randomiza-
tion study of birthweight to date, and it indicates 
that intrauterine growth restriction, as reflected by 
lower birthweight, is causally and directly related 
to increased susceptibility to coronary artery dis-
ease and type 2 diabetes mellitus in adulthood. 
This causal relationship is not mediated by adult 
obesity or hypertension. Our study supports the 
notion that population-level interventions improv-
ing prenatal nutrition and growth may improve 
cardiometabolic disease profiles later in life.
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plus The Coronary Artery Disease [C4D] Genetics),9 AFGen 
(Atrial Fibrillation Genetics),10 ISGC (International Stroke 
Genetics Consortium),11 ICBP (International Consortium 
for Blood Pressure),12 GIANT (Genetic Investigation of 
Anthropometric Traits),13,14 GLGC (Global Lipids Genetic 
Consortium),15 DIAGRAM (Diabetes Genetics Replication and 
Meta-Analysis),16 and MAGIC (Meta-Analysis of Glucose and 
Insulin Related Traits Consortium)17 investigators, respectively.
Study Sample
The UKB is a longitudinal cohort study of >500 000 individu-
als aged 40 to 69 years initiated in the United Kingdom in 
2006–2010.7 We included 237 631 participants who knew 
their birthweight; to focus on the linear effects of birthweight, 
we limited analysis to individuals reporting birthweight to 
be within 2.5 and 4.5 kg and excluded individuals with car-
diovascular disease prior enrollment (Methods section and 
Table I in the Data Supplement). We used UKB for our obser-
vational analyses, as well as to perform a GWAS of SBP and 
DBP (as publically available summary statistics were adjusted 
for BMI) to create an instrumental variable (IV) for the MR 
analyses. Cardiovascular outcomes for observational studies 
were defined using the International Classification of Diseases 
codes (details in Methods section in the Data Supplement). 
The exposure of interest was self-reported birthweight.
For our MR analyses, we used publicly available GWAS sum-
mary statistic of birthweight 8 as exposure and of CAD,9 AF,10 
IS,11 SBP and DBP (adjusted for BMI),12 BMI,13 WHR,14 HDL, LDL, 
triglycerides,15 T2D,16 2-hour glucose,17 fasting glucose, and 
fasting insulin18 as outcomes. Details on the GWAS consortia, 
number of samples, proportion of variance explained, and sta-
tistical power for MR analysis are presented in the Table.
Statistical Methods
Observational Analyses
After confirming normal distribution of all continuous vari-
ables, we performed multivariable linear regression models to 
assess associations of birthweight with SBP, DBP, BMI, body 
fat, and WHR and multivariable logistic regression models to 
study associations of birthweight with T2D and lipid medica-
tions. Multivariable-adjusted Cox proportional hazards mod-
els were performed to assess associations of birthweight with 
CAD, AF, IS, hemorrhagic stroke, and heart failure events, 
separately during a median follow-up of 6.1 years (maximum 
6.7 years). We use the DAGitty web tool (http://dagitty.net/
dags.html) to systematically construct our multivariable model 
adjusting for confounders (Figure I in the Data Supplement). 
All association analyses were adjusted for age, sex, region of 
the UKB assessment center, ethnicity, maternal smoking, and 
Townsend index. We assessed evidence of nonlinear effects 
of birthweight on different outcomes using spline regres-
sion models. We excluded any violation of the proportion-
ality assumption in our Cox regression analyses (all P>0.30) 
by Schoenfeld residuals test. All observational analyses were 
performed in the UKB.
Mendelian Randomization
We performed 2-sample MR analyses using publically avail-
able consortia data, except for blood pressure where we 
performed a GWAS in UKB. We assessed the causal rela-
tionships of birthweight with CAD, AF, IS, and T2D and risk 
factors for these diseases (SBP, DBP, BMI, WHR, HDL, LDL, 
triglycerides, 2-hour glucose, fasting glucose, and fasting 
insulin) using the 2-sample MR approach.19,20 To minimize the 
risk of pleiotropy affecting our results, we performed analyses 
using 3 different IVs:
IV1:  Including up to 58 independent lead variants (exclud-
ing the insulin-like growth factor 2 [IGF2] locus 
because of imprinting; see Methods section in the 
Data Supplement) from the GWAS of birthweight per-
formed by the EGG consortium8;
IV2:  Including up to 46 variants after exclusion of 12 vari-
ants associated with CAD, AF, IS, and T2D at GWAS 
significance; any confounders at GWAS significance; 
or with any of the confounders or CAD, AF, IS, and 
T2D at a P value lower than the P value for asso-
ciation with birthweight (Figure II and Table II in the 
Data Supplement). These associations were esti-
mated in UKB.
IV3:  Excluded 1 to 9 heterogeneous variants (different for 
each outcome; Figure III in the Data Supplement). We 
performed a stepwise downward model selection in 
which SNPs were iteratively removed from the risk 
score until the heterogeneity test was no longer sig-
nificant at the prespecified threshold (P<0.05) using 
the R package gtx.
We decided a priori that IV2 would constitute our main 
model (balancing high statistical power and low risk of pleiot-
ropy) but included IV1 to maximize power and IV3 to decrease 
risk of pleiotropy in sensitivity analyses.
We performed 2-sample MR using 4 separate methods to 
estimate causal effects for binary and continuous outcomes: 
the standard inverse-variance weighted regression, the robust 
penalized inverse-variance weighted, and 2 robust regression 
methods, the weighted median-based method and Egger 
regression.20 We performed leave-one-out sensitivity analyses 
to identify whether a single SNP was driving an association. 
To further address whether birthweight had a causal effect 
on CAD and T2D independently of BMI, we used a multi-
variate MR weighted regression-based method, in which the 
causal effects of multiple related risk factors can be estimated 
simultaneously.21,22
We estimated statistical power for the different MR 
analyses (Table) using sample sizes and variance explained 
specific for each analysis and an α threshold of 0.05 for 2 
different effect sizes: (1) assuming a fixed effect across phe-
notypes of 0.15 SD (continuous outcomes) or 20% (odds 
ratio, 1.2; dichotomous outcomes) and (2) for traits that 
were available in UKB, the effect size from observational 
analyses.
MR analyses were conducted with the R packages 
TwoSampleMR23 and MendelianRandomization.24 Power 
for MR analyses was estimated with an online tool by 
Burgess (https://sb452.shinyapps.io/power/). Observational 
analyses were conducted with the R package Survival (ver-
sion 3.3.0).
A flow chart of the different data sources used in this 
study is shown in Figure IV in the Data Supplement. A detailed 
description of material and methods can be found in the 
Methods section in the Data Supplement.
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RESULTS
In UKB, the mean age at baseline was 55.0 years (SD, 
8.1 years) and 61% of subjects were females. During 
follow-up, 5542 incident cardiovascular disease cases 
occurred in participants free from the disease at base-
line (2656 CAD; 1580 AF; 688 IS; 363 hemorrhagic 
stroke; and 255 heart failure events; Tables I and III in 
the Data Supplement).
Observational Analyses
The results from observational analyses are sum-
marized in Figure (full results in Table III in the Data 
Supplement). We observed strong inverse associa-
tions between birthweight and blood pressure, CAD, 
T2D, and lipid-lowering treatment. In contrast, we 
observed strong and positive associations between 
birthweight and BMI and body fat percentage. After 
adjusting for multiple testing (12 traits), the associa-
tions were nonsignificant for WHR, AF, IS, hemorrhag-
ic stroke, and heart failure. We excluded nonlinear 
associations between birthweight and any outcomes 
tested (P>0.05) by spline regression (Figure V in the 
Data Supplement).
Mendelian Randomization
In our main analyses (inverse-variance weighted using 
the 46-SNP IV [IV2]), we found evidence of causal asso-
ciations of birthweight with BMI, LDL, 2-hour glucose, 
CAD, and T2D (Figure). The direction of the effect was 
negative for all the above outcomes (ie, higher birth-
weight was associated with lower risk and vice versa), 
with the exception of BMI, where higher birthweight 
was associated with higher BMI. We did not find evi-
dence of causal effect of birthweight on HDL, triglycer-
ides, fasting insulin, AF, and IS.
The leave-one-out sensitivity analysis did not high-
light any heterogeneous SNPs with a large effect on 
the results. After excluding heterogeneous SNPs in the 
IV3, our analysis showed no significant heterogeneity 
and no significant directional horizontal pleiotropy (all 
P>0.05; Figure VI in the Data Supplement).
The analyses using penalized robust inverse-variance 
weighted, MR Egger, and weighted median methods 
Table. Description of Data Used and Statistical Power for Mendelian Randomization Analyses
Phenotype Consortium
No. of 
Samples
Variants 
in the IV2
Variance 
Explained, 
%
Effect in 
UKB
Power for 
Observed 
Association, 
%
Power 
for Fixed 
Standardized 
Effect, % Reference
BW, SD, kg/m2 EGG 143 677 … … … … … Horikoshi et al8
CAD, log odds CARDIoGRAMplusC4D 184 305 45 0.022 0.854 99 100 Nikpay et al9
AF, log odds AFGen 133 073 39 0.020 1.179 84 90 Christophersen 
et al10
IS, log odds ISGC 435 001 45 0.022 0.881 94 99 Pulit et al11
SBP, mm Hg UKB 337 229 33 0.022 −0.042 95 100 Sudlow et al7
DBP, mm Hg UKB 337 235 33 0.022 −0.025 58 100
SBP, mm Hg ICBP 201 529 34 0.020 −0.042 76 100 Ehret et al12
DBP, mm Hg ICBP 201 529 34 0.020 −0.025 35 100
BMI, SD, kg/m2 GIANT 339 224 38 0.020 0.041 92 100 Locke et al13
WHR, SD GIANT 210 082 38 0.020 0.003 4 100 Shungin et al14
HDL, SD, mg/dL GLGC 187 167 38 0.020 NA NA 100 Willer et al15
LDL, SD, mg/dL GLGC 173 082 38 0.020 NA NA 100
TG, SD, mg/dL GLGC 177 861 37 0.020 NA NA 100
T2D, log odds DIAGRAM 149 821 17 0.012 0.832 92 91 Morris et al16
2-h glucose, mmol/L MAGIC 42 854 17 0.010 NA NA 87 Scott et al17
Fasting glucose, mmol/L MAGIC 58 074 38 0.020 NA NA 99 Manning et al18
Fasting insulin, log pmol/L MAGIC 51 750 38 0.020 NA NA 99
Characteristics of the consortia used in our study: number of samples, number of SNP included in the IV2 for different outcomes, proportion of phenotype variance 
explained by the instruments (tested in UKB), statistical power for a fixed effect of 0.15 SD (continuous traits) or 20% (binary traits) per SD change in BW, β (continuous 
traits), OR (T2D), or HR (cardiovascular outcomes) from observational analyses in UKB and statistical power calculated for this observed association. AF indicates atrial 
fibrillation; AFGen, Atrial Fibrillation Genetics; BMI, body mass index; BW, birthweight; CAD, coronary artery disease; CARDIoGRAMplusC4D, Coronary Artery Disease 
Genome wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease (C4D) Genetics; DBP, diastolic blood pressure; DIAGRAM, Diabetes 
Genetics Replication and Meta-Analysis; EGG, Early Growth Genetics; GIANT, Genetic Investigation of Anthropometric Traits; GLGC, Global Lipids Genetic Consortium; 
HDL, high-density lipoprotein; HR, hazard ratio; ICBP, International Consortium for Blood Pressure; IS, ischemic stroke; ISGC, International Stroke Genetics Consortium; 
IV2, instrumental variable 2; LDL, low-density lipoproteins; MAGIC, Meta-Analysis of Glucose and Insulin Related Traits Consortium; OR, odds ratio; SBP, systolic blood 
pressure; SNP, single-nucleotide polymorphism; T2D, type 2 diabetes mellitus; TG, triglycerides; UKB, UK Biobank; and WHR, waist-to-hip ratio.
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consistently yielded similar effect estimates but as expect-
ed with wider confidence intervals, especially for Egger 
regression (Table IV and Figure VII in the Data Supplement). 
Further, sensitivity analyses using alternative IVs with high-
er power (IV1) and lower risk of pleiotropy (IV3) also pro-
vided similar results (Table IV in the Data Supplement).
The mediation analysis using the multivariate MR 
weighted regression-based method showed an inde-
A
B
Figure. Inverse-variance weighted (IVW) 
estimates from Mendelian randomization (MR) 
analyses and association results (BETA/ hazard 
ratio [HR]/odds ratio [OR]) from observational 
analyses of birth weight (BW) with cardiovascu-
lar outcomes in UK Biobank (UKB) using multi-
variable-adjusted linear and logistic regression, 
and multivariable-adjusted Cox proportional 
hazards models. A, Continuous outcomes: 
systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) in UKB, body mass index 
(BMI), waist-to-hip ratio (WHR), high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), 
triglycerides (TG), body fat percentage (BF), 2-h 
glucose, fasting  glucose, and fasting insulin. 
B, Binary outcomes: coronary artery disease 
(CAD), atrial fibrillation (AF), ischemic stroke 
(IS), hemorrhagic stroke (HS), heart failure (HF), 
type 2 diabetes mellitus (T2D), and lipid medi-
cations (LIP). The β values from linear regression 
represent SD change in outcome variable per 
SD change in BW, except for SBP and DBP 
where they represent the outcome in raw unit 
(mm Hg) per SD change in BW. MR analyses 
were based on the 46 variants included in the 
instrument variable 2 using data sources listed 
in the Table. All effects for the IVW (β or OR) 
are given in original units as provided by the 
consortia. Model adjustment: age, sex, region 
of the UKB assessment center, ethnicity, mater-
nal smoking, and Townsend index. CI indicates 
confidence interval; and N, number of variants 
included in the instrument variable.
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pendent association between birthweight and CAD, as 
well as between birthweight and T2D, not mediated by 
BMI in either case. The direction of the effect detected 
was consistent with our main MR analyses (Table IV in 
the Data Supplement).
We had good statistical power to detect causal asso-
ciations for all traits when assuming a fixed effect across 
phenotypes of 0.15 SD (continuous outcomes) or 20% 
(odds ratio, 1.2; dichotomous outcomes). When using 
the effect sizes from observational analyses of traits 
that were available in UKB, the power was adequate 
for all traits except DBP and WHR.
DISCUSSION
Principal Findings
In this study of 237 631 individuals from the general 
population, we used self-reported birthweight as a 
proxy for fetal development to analyze downstream 
consequences of intrauterine growth restriction. We 
describe the association of birthweight with incidence of 
T2D and 5 cardiovascular outcomes (CAD, AF, IS, hem-
orrhagic stroke, and heart failure) and cardiometabolic 
risk factors (blood pressure, BMI, body fat, and WHR), 
and we identify a causal role of birthweight in the devel-
opment of several cardiometabolic diseases. Our princi-
pal findings are several. First, in our observational study, 
we established that self-reported birthweight displays 
strong inverse associations with blood pressure, CAD, 
and T2D and strong direct associations with BMI and 
body fat. Second, our MR analyses indicate that low 
birthweight, used as a proxy for intrauterine growth 
retardation, is causally related to higher risk of LDL and 
2-hour glucose and higher CAD and T2D in adults. This 
highlights the influence of prenatal determinants of 
fetal growth on the development of cardiometabolic 
diseases in adulthood. Third, our study suggests high 
birthweight to be causally associated with increased BMI 
but not causally associated with blood pressure. Taken 
together and considering the different direction of the 
causality for BMI and CAD/T2D (higher birthweight 
increases BMI; lower birthweight increases CAD and 
T2D), our results suggest a plausible causal association 
of intrauterine growth restriction and low birthweight 
with risk for CAD and T2D, an association that does not 
seem to be mediated by obesity or hypertension.
In their initial description of the thrifty phenotype 
hypothesis,3 Barker and Hales proposed that BMI would 
be a possible mediator of the associations detected 
between low birthweight and adult T2D and CAD. The 
hypothesized primary effect of BMI was supported by 
evidence from both population and experimental stud-
ies linking low birthweight with predisposition to an 
increased risk of metabolic diseases, such as T2D,25–29 
hypertension,30,31 and CAD.32 However, in our study 
and in prior observational analyses, higher birthweight 
is associated with obesity (a universally recognized cor-
relate of cardiometabolic disease) in both childhood33,34 
and adulthood.8,35 Our findings suggest a plausible 
causal association of low birthweight with CAD and 
T2D, which is uniquely independent of the relationship 
between high birthweight and increased BMI. Consis-
tent with our observed effects of low birthweight on risk 
for CAD and T2D independent of adult obesity, a recent 
study of black women failed to detect a causal role for 
BMI in mediating the increased risk for T2D in adult life 
among individuals with low birthweight.36 New models 
for how risk for cardiometabolic disease in adulthood is 
directly conferred by growth restriction in utero without 
a compensatory change in BMI are needed to explain 
our observation of a direct causal relationship.
Explicit in the Barker hypothesis and explored by the 
experimental literature37,38 is a model in which prena-
tal growth stress leads to metabolic reprogramming 
beginning in utero. In the setting of prenatal malnutri-
tion, the fetus is hypothesized to shift toward insulin 
resistance to allow for maximum uptake of available 
energy and nutrients. In this hypothesis, the persistence 
of insulin resistance after parturition might then trigger 
rapid postnatal growth with the concomitant poten-
tial for increased long-term risk of T2D, obesity, and 
CAD in adulthood.25,39 However, our findings support a 
separate direct causal link between intrauterine growth 
restriction and long-term risk for cardiometabolic dis-
ease, which does not involve adult obesity. Consistent 
with our detection of a causal relationship, one prior 
report using IV analyses, but with much fewer variants, 
also described a direct causal association between low 
birthweight and T2D.5
In contrast to our results, Au Yeung et al,6 reported 
no causal association between birthweight and CAD. 
However, this study was based on a weak IV consist-
ing of 7 SNPs, explaining only 0.45% of the variance 
in birthweight (in contrast to our score that explained 
2.2% of the variance), resulting in limited statistical 
power of 56% suggested by post hoc calculations. In 
this context, it is also worth mentioning the genetic 
correlation analyses of birthweight with several health-
related traits, published in the recent GWAS for birth-
weight used to create IVs for our MR study.8 As in our 
study, they reported strong positive genetic correlations 
with BMI, and inverse genetic correlations with CAD 
and T2D. In contrast to our MR results, they highlight 
a negative genetic correlation with SBP. This discrep-
ancy is probably related to the different methods used. 
Indeed, they used the linkage-disequilibrium score 
regression model,40 which use all GWAS summary sta-
tistics of the traits of interest to estimate the genetic 
correlations, while MR methods are based on a much 
smaller number of variants, aiming to decrease the risk 
of horizontal pleiotropy driving associations.
D
ow
nloaded from
 http://ahajournals.org by on August 20, 2018
Zanetti et al; Birthweight, T2D, and Cardiovascular Disease
Circ Genom Precis Med. 2018;11:e002054. DOI: 10.1161/CIRCGEN.117.002054 June 2018 7
Clinical Implications
Our observation that low birthweight is causally relat-
ed to LDL, 2-hour glucose, CAD, and T2D, is consis-
tent with the growing recognition of the long-term 
public health importance of supporting adequate pre-
natal nutrition. Diet is a broadly modifiable risk fac-
tor, and both maternal and paternal nutrition have 
an impact on the risk of metabolic syndrome, lipid 
dysregulation, fat deposition, obesity, and hyperten-
sion in offspring via a hypothesized mechanism of in 
utero epigenetic imprinting.41–43 Both epidemiological 
and animal studies highlight that undernutrition, over-
nutrition, and inadequate diet composition negatively 
impact fetoplacental growth and metabolic patterns, 
potentially having adverse later life metabolic effects 
in the offspring.44 Additionally, our data may also offer 
a window into the role by which nonnutritional fac-
tors affecting fetal growth, such as congenital heart 
disease and premature birth, may predispose affected 
individuals to long-term risk of cardiometabolic disease 
in adulthood.45–47
Our results indicate that some proportion of com-
mon chronic diseases of adulthood could potentially be 
reduced by achieving optimal fetal nutrition. Short-term 
follow-up of children born after randomized nutritional 
interventions in pregnancy describe beneficial effects 
on growth, vascular function, lipid levels, glucose tol-
erance, and insulin sensitivity, although longer-term 
studies examining nutrition and growth in premature 
infants display a more complex set of relationships.48,49 
Considered in the context of populations, our data 
suggest that attention to prenatal nutrition and intra-
uterine growth may have long-term consequences 
regarding the risk of CAD, obesity, and diabetes mel-
litus in adult life.
Strengths and Limitations
To our knowledge, this is the largest and most compre-
hensive study of associations of birthweight with outcome 
to date. Additionally, we used 3 different IVs to maximize 
power and to decrease risk of pleiotropy and several 
methods for MR analyses all yielding consistent effects 
for the tested hypotheses. However, our study is limited 
by the study samples of middle-aged to elderly individuals 
of European descent from a rich country. Hence, gener-
alizability of our findings to other populations where the 
diet, prenatal care, prevalence, and predispositions of car-
diometabolic disease are different is unknown. Further, 
although we excluded variants with higher likelihood of 
pleiotropy from our analysis and applied a range of sen-
sitivity analyses and methods robust to pleiotropy, little is 
known about the mechanisms underlying loci included in 
the IV. Although our comprehensive analytic framework 
did not indicate any presence of horizontal pleiotropy, it 
is possible that some or all of these loci may also have a 
direct influence on the processes leading to CAD or T2D 
independent of intrauterine growth. In addition, despite 
the large sample in this study, statistical power to detect 
potentially causal relationships was limited for some 
traits, at least for the effect sizes from our observational 
analyses (in particular, DBP and WHR; Table). Finally, our 
design did not take into account maternal genetic varia-
tion, which may influence fetal growth indirectly through 
the intrauterine environment. Indeed, birthweight can be 
considered as the result of a developmental process start-
ed at conception and influenced by many factors during 
pregnancy, and future MR studies could be designed to 
consider both maternal and fetal genotypes as instru-
ments for intrauterine exposures.
Conclusions
In conclusion, we demonstrate that intrauterine growth 
restriction, as evidenced by lower birthweight, is causally 
related with increased susceptibility to T2D and CAD but 
that this effect is independent of adult hypertension or 
obesity, which has been previously hypothesized to be 
mediators of such an association. Our study supports the 
notion that population-level interventions improving pre-
natal nutrition and growth may improve cardiometabolic 
disease profiles later in life, but this needs to be confirmed 
using other study designs, such as large-scale communi-
ty-based intervention trials, and MR analyses performed 
with both maternal and fetal genotypes as instruments.
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